Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15184MR)

This product GTTS-WQ15184MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15184MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9365MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ4562MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ13923MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ15342MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ1204MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ13285MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ9868MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ13317MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW